BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
47.37
+0.10 (0.21%)
At close: Aug 1, 2025, 4:00 PM
46.91
-0.46 (-0.97%)
After-hours: Aug 1, 2025, 7:48 PM EDT
CTI BioPharma Market Cap
BridgeBio Pharma has a market cap or net worth of $8.99 billion as of August 1, 2025. Its market cap has increased by 64.33% in one year.
Market Cap
8.99B
Enterprise Value
10.31B
1-Year Change
64.33%
Ranking
Category
Stock Price
$47.37
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $8.99B, an increase of 170.94%. That is a compound annual growth rate of 17.75%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2025 | 8.98B | 73.08% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | 8.72B | 101.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 678.73B |
| Johnson & Johnson | 399.90B |
| AbbVie | 343.09B |
| AstraZeneca | 232.21B |
| Novartis AG | 224.47B |
| Abbott Laboratories | 221.63B |
| UnitedHealth Group | 219.26B |
| Novo Nordisk | 213.92B |